RachelleS.DoodyMD
Neurology • Houston, TXDistinguished Emeritus Professor Neurology Baylor College of Medicine Past Effie Marie Cain Chair in Alzheimer's Disease Research Baylor College of Medicine Past Director Alzheimer's Disease and Memory Disorders Center Baylor College of Medicine Past Program Director Alzheimer's Disease and Dementia Fellowship Baylor College of Medicine
Are you Dr. Doody?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 65 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
6550 Fannin St
Suite 1801
Houston, TX 77030Phone+1 713-798-5975Fax+1 713-798-5864
Summary
- Dr. Rachelle Doody, MD is a board certified neurologist in Houston, Texas. She is currently licensed to practice medicine in Texas. She is affiliated with Houston Methodist Hospital and St. Luke's Health - Baylor St. Luke's Medical Center.
Education & Training
Baylor College of MedicineResidency, Neurology, 1984 - 1987
McGill University Faculty Medicine HospitalInternal Medicine, 1983 - 1984- Baylor College of MedicineClass of 1983
Certifications & Licensure
TX State Medical License 1983 - 2024- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2010-2014
- Top Doctors:SE Texas Castle Connolly, 2013
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext Start of enrollment: 2013 Mar 01
- The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF) Start of enrollment: 2014 Jan 08
- Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss Start of enrollment: 2014 Feb 28
Publications & Presentations
PubMed
- 42 citationsA Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline DataGennaro Pagano, Frank G. Boess, Kirsten I. Taylor, Benedicte Ricci, Brit Mollenhauer
Frontiers in Neurology. 2021-10-01 - 49 citationsSafety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phas...Daniel K. Burns, Robert Alexander, Kathleen A. Welsh-Bohmer, Meredith Culp, Carl Chiang
The Lancet. Neurology. 2021-07-01 - 192 citationsA trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.Stephen Salloway, Martin R. Farlow, Eric McDade, David B. Clifford, Guoqiao Wang
Nature Medicine. 2021-06-21
Press Mentions
CTAD 2022: Pivotal Anti-Amyloid Data and New Pathways (Updated)December 1st, 2022- Clinical Trial Set for Gantenerumab in Early-Onset Alzheimer’s DiseaseJanuary 11th, 2022
- New Alzheimer’s Prevention Trial in Young PeopleDecember 20th, 2021
- Join now to see all
Grant Support
- Muscle Strength Measurements In Self-NeglectorsNational Center For Research Resources2004–2006
- Core--ClinicalNational Institute On Aging1995–2000
- Alzheimers Disease Research CenterNational Institute On Aging1998
- Pilot Study--Semantics Of Sentence Accent In Alzheimer'S DiseaseNational Institute On Aging1989–1994
